Company: INGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029993
Chunk: 173

Company: Inogen Inc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1A
Chunk 173
---
ated Appropriations Act extended the higher 75/25 blended rates in non-CBAs until December 31, 2023. As of January 1, 2024, the rates in former non-CBAs were reduced to the former CBA rates listed in the table above. Rates in rural areas continue to be based upon a 50/50 blended rates, consistent with CMS' December 2021 final rule described above.

    Average Medicare reimbursement rates in non-former CBAs, non-rural areas
     
    E1390

    E1392

    As of January 1, 2025
     
    $
    96.42

    $
    47.51

    As of January 1, 2024
     
    $
    93.61

    $
    46.12

    As of January 1, 2023
     
    $
    125.41

    $
    46.49

    As of January 1, 2022
     
    $
    115.14

    $
    43.69

    As of April 1, 2021
     
    $
    109.39

    $
    42.12

    As of January 1, 2021 (retroactively revised March 1, 2021)
     
    $
    104.07

    $
    40.06

    As of January 1, 2020
     
    $
    74.84

    $
    36.87

    As of January 1, 2019
     
    $
    72.32

    $
    35.64

    As of January 1, 2018
     
    $
    69.31

    $
    38.10

CMS is required to conduct future rounds of competitive bidding, which could reduce reimbursement rates, negatively impact the premium for POCs over other oxygen modalities, or limit beneficiary access to our technologies. 

We cannot guarantee that we will be offered contracts in subsequent rounds of competitive bidding. In all five rounds of competitive bidding in which we have participated, we have gained access to certain CBAs and been excluded from other CBAs. 

Medicare revenue, including patient co-insurance and deductible obligations, represented 9.5% of our total revenue in the year ended December 31, 2024 and